ThalysBio founded in 2002, is a wholly-owned subsidiary of Thalys (stock code: 603716), which is a national high-tech enterprise with R&D, production and sales of in vitro diagnostic products as its main business, a small giant enterprise of Hubei Province, a clinical in vitro diagnostic reagent engineering research center, a top 100 innovative enterprise in Wuhan, and a research and development center in Wuhan.
ThalysBio headquartered in Wuhan, Hubei Province, and has set up “Wuhan, Hubei Province & Liuyang, Hunan Province”, a dual industry research and manufacturing base of nearly 15,000 square meters, to create a linkage model of innovative medical professional services and high-end IVD manufacturing.
We have established two R&D platforms for clinical diagnostic reagents and clinical testing and analytical instruments, and continue to promote the “localization” and “serialization” of reagents and instruments. Meanwhile, ThalysBio have formed a R&D layout covering thrombosis and hemostasis, fluorescence immunity (POCT), chemiluminescence, autoimmunity, cytokines, microbial testing and other product series.
Strictly controlling product quality, continuous and innovative research and development, oriented to clinical needs, ThalysBio combining internal and external development strength to forming an innovative mode of “industry, academia, research and medicine”, and contributing to the common progress of testing technology and clinical medicine.
武汉塞力斯生物技术有限公司(以下简称:塞力斯生物)创立于2002年,是塞力斯医疗科技集团股份有限公司(股票代码:603716)的全资子公司,是以体外诊断产品的研发、生产和销售为主营业务的国家高新技术企业,同时也是湖北省临床体外诊断试剂工程研究中心、武汉市科技小巨人企业、武汉市百强创新企业、武汉市研究开发中心。
塞力斯生物总部位于湖北省武汉市,自有2.7万平方米产业园,拥有2000平方米符合医疗器械GMP标准的诊断产品生产基地。此外,在湖南长沙建有8000平方米的仪器和试剂生产基地(湖南IVD创新智造基地)。作为国内第一批规模化生产血栓与止血诊断试剂的生产商,创建了临床体外诊断试剂和临床检测分析仪器两大研发技术平台,逐步推进实现试剂和仪器的“系列化”、“一体化”发展目标,并形成了覆盖凝血、荧光免疫(POCT)、化学发光、自身免疫诊断、微生物检测等多产品开发布局。
M.S., School of Basic Medical Sciences, Jiaotong University School of Medicine;
M.S., McCombs School of Business, University of Texas at Austin, U.S.A.
Mr. Wang is currently the President of Thalys and the General Manager of ThalysBio.
Mr. Wang has been engaged in the IVD clinical diagnostic and medical device industry, with rich experience in technological innovation, product management, company strategy management, business operation and international marketing. Meanwhile, he also has rich industry experience and connections in various fields such as molecular diagnostics, bedside diagnostics, central laboratory diagnostics, and clinical medical device marketing.
Doctor of Preventive Medicine and Postdoctoral Fellow at Tongji Medical College of Huazhong University of Science & Technology, Senior Engineer, Senior Economist
Currently, he is the Deputy General Manager of Thalys, Senior Vice President/Executive Director of ThalysBio.
Dr. Lu has participated in a number of national research projects (1 SARS project of the Ministry of Science and Technology of China, 2 projects of the National Natural Science Foundation of China), and has published more than 20 papers in domestic and international renowned academic journals, including 8 papers in SCI.
Dr. Lu has long been committed to medical device innovation and development, technical cooperation, registration and certification, production standardization management and market transformation. Since 2010, he has been responsible for setting up the biotechnology coagulation R&D team, establishing the R&D center laboratory, setting up the production process system, and leading the R&D team to continuously achieve breakthroughs in the field of coagulation in vitro diagnostics.
Chengdu University of Traditional Chinese Medicine, majoring in Pharmaceutical Preparation.
Mr. Chen is the Assistant President of the Group, the National Sales Director of Wuhan ThalysBio and the General Manager of the Regional Medical Laboratory Center Business Unit.
Mr. Chen is dedicated to marketing management, sales strategic planning, resource management and sales team management in the biopharmaceutical industry. Mr. Chen is in charge of the national sales management and business development of ThalysBio. He actively adapts to the needs of the Group’s business strategy development under the new situation, establishes and builds a composite sales elite team, and leads the team to grasp all the sales opportunities, so that the company’s products can rapidly land in the regionalization of a wide range of markets.
Master of Medicine, Peking Union Medical College
Currently National Marketing Director of Wuhan ThalysBio
Mr. Zhou is in charge of the product marketing of ThalysBio, formulating marketing strategies and activities, as well as the management and configuration of the marketing team. Mr. Zhou specializes in introducing and setting up domestic technical support system, building marketing and sales channels.
研发&生产领军人
鲁翌先生,毕业于华中科技大学同济医学院,并取得预防医学学士学位,卫生检验学硕士学位,医学博士及博士后,高级工程师,高级经济师。曾参与多项国家级课题研究,在国内外知名学术期刊上发表论文20余篇,SCI收录8篇。主持并完成政府资助开发课题7项,入选武汉市“黄鹤英才”“金山英才”计划及武汉市博士人才资助计划。 自2009年8月加入塞力斯集团,鲁翌先生长期致力于医疗器械创新开发、技术合作、注册认证、生产标准化管理及上市转化,现任武汉塞力斯生物技术有限公司高级副总裁、湖南塞力斯生物技术有限公司总经理、湖南赛新生物科技有限公司总经理、湖南赛迪亚生物科技有限公司执行董事、(塞力斯)湖北省体外诊断试剂工程技术中心主任。
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
湖南IVD创新智造基地
湖南IVD创新智造基地坐落于湖南浏阳经济开发区,是塞力斯生物位于湖南省的首批挂牌IVD智造基地。基地于2020年10月挂牌成立,2021年12月正式竣工。建筑面积8000 m²,包括万级、十万级净化厂房3000 m²,仪器生产车间2000 m²,各类仓库2000 m²,研发中心实验室1000 m²,拥有可覆盖液体试剂、干式化学试剂、冻干试剂、有源仪器等各类体外诊断产品的生产线。目前已形成以湖南赛新生物科技有限公司和湖南塞力斯生物技术有限公司为双主体的创新基地。
其中,湖南赛新主要承担创新项目自主研发、对外合作技术项目成果的吸收和转移、创新产品临床注册;湖南塞力斯主攻智能制造,专注于IVD仪器和试剂的精益化生产。双主体通过功能互补、产业生态,打造产研协同驱动的一体化智造平台。
湖南IVD创新智造基地
湖南IVD创新智造基地坐落于湖南浏阳经济开发区,是塞力斯生物位于湖南省的首批挂牌IVD智造基地。目前已形成以湖南赛新生物科技有限公司和湖南塞力斯生物技术有限公司为双主体的创新基地。
其中,湖南赛新主要承担创新项目自主研发、对外合作技术项目成果的吸收和转移、创新产品临床注册;湖南塞力斯主攻智能制造,专注于IVD仪器和试剂的精益化生产。双主体通过功能互补、产业生态,打造产研协同驱动的一体化智造平台。
© 2022 Thalysbio. All rights reserved 鄂ICP备2023001689号-1